AstraZeneca initially invested in Moderna in 2013. With this most recent investment, the British drugmaker boosted its stake in the biotech to 9 percent.
Messenger RNA — which holds the recipe for making proteins in the body — could play a key role in addressing many hard-to-treat diseases like cancer, heart infections and kidney disorders.
Moderna is conducting two Phase I studies for infectious disease vaccines based on the mRNA and is awaiting approval to run a third study of a vascular disease treatment.
Along with AstraZeneca, Moderna also has strategic agreements with New Haven, Conn.-based Alexion Pharmaceuticals, Kenilworth, N.J.-based Merck and Boston-based Vertex Pharmaceuticals.
More articles on supply chain:
Some Olympic athletes use prescription drugs for ‘legal doping’
In Missouri, uptick in criminal activity linked to prescription drugs
Abbott to launch unified network of diagnostic systems
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
